MktsMarkets

Neurogene Inc.
NASDAQ: NGNEKey statistics
NGNE News
Stories mentioning NGNE from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 925.00 | ||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | ||||||
| Operating Expenses | ||||||||
| Research & Development | 25,150 | 20,644 | 17,241 | 19,366 | 17,760 | 15,347 | 16,285 | 15,744 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 33,349 | 27,530 | 23,798 | 26,081 | 25,919 | 21,512 | 22,180 | 21,059 |
| Operating Income (Loss) | (33,349) | (27,530) | (23,798) | (26,081) | (25,919) | (21,512) | (22,180) | (20,134) |
| Interest Income | 2,261 | 2,674 | 2,739 | 2,928 | 3,206 | 2,270 | 1,842 | 2,035 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (30,934) | (24,735) | (20,953) | (22,016) | (22,647) | (19,514) | (20,217) | (18,492) |
| Earnings Per Share (Basic) | (1.39) | (1.16) | (0.99) | (1.05) | (1.08) | (1.11) | (1.19) | (1.09) |
| Earnings Per Share (Diluted) | (1.39) | (1.16) | (0.99) | (1.05) | (1.08) | (1.11) | (1.19) | (1.09) |
| Weighted Average Shares Outstanding (Basic) | 22,306 | 21,326 | 21,168 | 21,055 | 20,996 | 17,567 | 16,953 | 16,942 |
| Weighted Average Shares Outstanding (Diluted) | 22,306 | 21,326 | 21,168 | 21,055 | 20,996 | 17,567 | 16,953 | 16,942 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About NGNE
Neurogene Inc. (NASDAQ: NGNE) is a stock listed on the Nasdaq Stock Market under the ticker symbol NGNE. It last traded at $30.85 (Oct 28, 2026, 3:38 PM ET), up 14.3% on the day. That gives Neurogene a market capitalisation of $539.0M.
Over the past 52 weeks NGNE has traded between $15.93 and $43.66.
For the quarter ended Mar 31, 2026 it reported a net loss of $30.9M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$30.9M |
| Dec 31, 2025 | — | -$24.7M |
| Sep 30, 2025 | $0 | -$21.0M |
| Jun 30, 2025 | $0 | -$22.0M |
From Neurogene’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…